| Downgrades | Buy Neutral | X | ||
| Resumed | Buy | X | ||
| Initiated | Overweight | X | ||
| Upgrades | Sec Perform Outperform | X | ||
|
$7 $10 |
||||
| Upgrades | Underweight Neutral | X | ||
| Resumed | Equal-Weight | X | ||
|
$27 $10 |
||||
| Upgrades | Neutral Overweight | X | ||
|
$8 $16 |
||||
| Reiterated | Buy | X | ||
|
$29 $32 |
||||
| Reiterated | Outperform | X | ||
|
$15 $25 |
||||
| Downgrades | Overweight Neutral | X | ||
|
$21 $7 |
||||
| Reiterated | Underperform | X | ||
|
$15 $5 |
||||
| Downgrades | Neutral Underperform | X | ||
|
$15 $5 |
||||
| Upgrades | Underperform Neutral | X | ||
| Initiated | Buy | X | ||
| Upgrades | Neutral Outperform | X | ||
| Downgrades | Outperform Neutral | X | ||
|
$20 $19 |
||||
| Resumed | Outperform | X | ||
KPTI Karyopharm Therapeutics Inc.
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.
